Liraglutide and Semaglutide are both GLP-1 receptor agonists, primarily studied for their roles in metabolic health. Evidence from our corpus suggests their utility in managing overweight and obesity, often in combination with exercise, leading to improvements in body composition and metabolic parameters. Both peptides have also shown promise in improving cardiovascular outcomes, particularly in obese individuals with ASCVD but without type 2 diabetes, and in providing cardiorenal protection in type 1 diabetes. Liraglutide has been evaluated for glycemic control in type 2 diabetes, while Semaglutide has been investigated for early Alzheimer's disease.
| Liraglutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 479 | 1011 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | rct · 6 cohort · 2 review · 1 meta analysis · 1 in vitro · 2 | n/a |
| Studies with explicit sample size | 3 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Liraglutide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Liraglutide COA records so far — not enough for a meaningful purity aggregate yet. Browse what we have →
We tested 941 Semaglutide batches across 307 manufacturers, 99.54% avg purity.
No direct head-to-head trials in our corpus. Indirect comparison only. A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management over 68 weeks, suggesting a difference in dosing frequency and potential efficacy, though specific outcomes are not detailed in the summary. Semaglutide has also been studied in oral formulations, with a meta-analysis indicating that oral semaglutide 25 mg achieved exposure similar to subcutaneous 2.4 mg and led to greater weight loss in simulated studies. Liraglutide has been specifically explored for its efficacy in glycemic control against metformin monotherapy and metformin/glimepiride, and in combination with high-dose insulin for type 2 diabetes patients with severe insulin resistance. Semaglutide, on the other hand, has been investigated for potential links to non-arteritic anterior ischemic optic neuropathy risk and in phase 3 trials for early-stage symptomatic Alzheimer's disease.
Looking for vendor-level purity, endotoxin, and HPLC data on Liraglutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.